In the fall of 1999, a young chemical engineer named Todd Zion left his job at Eastman Kodak to enroll in the Ph.D. program at the Massachusetts Institute of Technology.
While looking for a subject to research, Zion noticed a grant proposal, never funded, that another graduate student had written on the subject of drug delivery. One possibility mentioned in the proposal was the development of a kind of insulin that would automatically respond to changes in blood-sugar levels, becoming active only when needed to maintain healthy levels around the clock. If it worked, the sugar-sensitive version could transform the lives of the six million people with diabetes in the United States who use insulin. No longer would they have to test their blood-sugar levels multiple times per day and try to calculate how much insulin to take. The self-regulating insulin would curtail high sugar levels, which raise the risk of long-term complications, and eradicate, or at least reduce, the most dangerous short-term complication: hypoglycemia, when sugar levels fall so low that they can cause confusion, unconsciousness, seizures and even death.
“I thought, Wow, that is a really neat area in which to do research,” Zion told me. Other researchers had been trying for 20 years to make insulin work only when needed. The first to publish a study were the scientists Michael Brownlee and Anthony Cerami, who in 1979 embedded a sugar-encrusted form of insulin in a mesh pouch with a sugar-loving protein called lectin. The idea was that when blood-sugar levels were elevated, the lectin would bind to the sugar in the blood and allow the insulin to leak out; when sugar levels were normal, the lectin would bind to the sugar-encrusted insulin, keeping it inside the pouch. But the system was impractical, because the pouch would need to be implanted under the skin and periodically refilled. And the lectin, derived from the jack-bean plant, was toxic.
In his first three years at M.I.T., Zion used nanoscale molecular engineering to create an insulin-lectin gel that could be injected without the need for an implanted pouch, while also rejiggering the lectin to make it less toxic. “It worked great visually,” he said. When the gel was placed in a sugar solution, “you could see the outer edge getting clear and dissolving . . . almost like an ice cube melting in water.”
The problem was that, no matter how hard he tried to manipulate the gel, the insulin either leaked out too easily, even when sugar levels were low, or not easily enough, when sugar levels were high.
Zion knew there was another approach: changing the insulin molecule itself, to make it sensitive to blood-sugar levels directly. But, he said, “almost everyone in the field of drug discovery believed that you should never, ever change the insulin molecule. . . . From a regulatory point of view, as soon as you manipulate the molecule, you’ve created a new drug. It doesn’t matter if you’ve attached a single atom to it.” Doing so, he knew, would require years of clinical trials in preparation for a new-drug application submission to the F.D.A. “That’s the only reason people were afraid.”
Zion’s trick was to attach a chemical arm — a short chain of sugars — directly onto the insulin molecule. (Attaching sugar to insulin? “Yes, it is a bit ironic,” he concedes.) The beauty of this approach is that it permits the insulin to latch directly onto the sugar-loving lectin in the gel — but only as needed. When blood-sugar levels are high, the lectin hooks up with any sugar floating freely from the blood, allowing the insulin molecule to do its normal job of connecting with insulin receptors on the surface of cells. (That is how insulin lowers blood-sugar levels, by merging with a cell’s insulin receptor and unlocking the cell membrane to allow sugar in.) When the sugar gets swallowed up by cells, lowering levels in the blood, the only remaining sweet for the lectin to attach to is the altered insulin’s sugar arm. Handcuffed to the lectin, the insulin can’t bind to insulin receptors. And so the insulin stops working to lower blood-sugar levels precisely when it’s no longer needed, because its sugar chain is held hostage by the lectin.
Zion called his new chemical creation smart insulin. In 2003, after testing it in rats, he won M.I.T.’s annual Entrepreneurship Competition. With the $30,000 prize money, he started a company called SmartCells and tried to see if he could make it work well enough to test it in humans.
The Latest on: Inventing drugs
via Google News
The Latest on: Inventing drugs
- Another road for Covid-19 vaccineson March 7, 2021 at 3:12 am
Western nations have the capacity in terms of economic potential and the legal and moral aspects to promote access to vaccines on a global scale.The outlook for the Covid-19 vaccine today can be ...
- Erythropoietin Drugs Market 2025 | Hospira, Johnson & Johnson, Amgen, Roche Holding AG, LG Life Sciences, Bioconon March 6, 2021 at 2:01 am
The latest report on Erythropoietin Drugs Market by Infinium Global Research gives complete coverage of the erythropoietin drugs market by drug class (biologics, biosimilars), product (epoetin-alfa, ...
- Teva Faces EU Antitrust Probe Over MS Drug Patent Strategyon March 5, 2021 at 11:10 am
European enforcers are investigating Teva over concerns the pharmaceutical company delayed the emergence of generic competitors to its blockbuster multiple sclerosis drug Copaxone by misusing patent ...
- Global Fibromyalgia Drugs Market Assessment 2021-2026 - Impact of COVID-19, Case Study Analysis, Key Opportunities and Major Playerson March 5, 2021 at 7:52 am
The report provides revenue of the globalFibromyalgia Drugs Market for the period 2016 and 2026, considering 2020 as ...
- Pfizer's Xalkori follow-up, which smoked the older drug in 1st-line patients, scores double win at the FDAon March 4, 2021 at 9:46 pm
Despite being the first to market in ALK-positive non-small cell lung cancer, Pfizer's Xalkori languished on the shelf as other competitors outpaced it. Now, after Pfizer's follow-up drug absolutely ...
- Teva faces EU antitrust probe over MS drug Copaxoneon March 4, 2021 at 6:26 pm
The European Commission has formally opened an antitrust investigation into Teva, which will assess whether the pharma company illegally delayed launches and use of generic versions of its blockbuster ...
- Vaccines perfectly safe: Technology, situation made invention possibleon March 3, 2021 at 11:07 am
Thinking people posed a valid query: how is it possible that an effective Covid-19 vaccine is already in hand? When frightening scourges like AIDS are difficult to contain even after decades of ...
- Astellas Sued Again Over Incontinence Drug Patenton March 1, 2021 at 7:54 am
A Novartis generic unit has slapped Astellas with litigation seeking to revoke the Japanese drug giant's patent for treating urinary concerns, just months after another generic company challenged the ...
- Re-inventing retail - Walmart’s Global CTO on cloud shifts, augmented reality and turning machine learning to cost-saving good useon February 26, 2021 at 4:41 am
The potential there is such that makes Walmart’s situation more optimistic as it looks beyond COVID, he argued: The thing that's different is technology. The Internet is different. Digital is ...
- What If We Pay People to Stop Using Drugs?on February 25, 2021 at 3:11 am
Traditional treatments often take place in expensive facilities, demand total abstinence, and rely on punitive methods of control. A harm reduction model turns all of that on its head.
via Bing News